Welcome to our dedicated page for Passage Bio SEC filings (Ticker: PASG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Passage Bio, Inc. (PASG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical stage genetic medicines company listed on the Nasdaq Capital Market, Passage Bio uses SEC filings to report financial results, material corporate events, and key developments in its PBFT02 gene therapy program for neurodegenerative diseases.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to see detailed information on research and development and general and administrative expenses, net loss, cash, cash equivalents, and marketable securities, along with risk factor and business discussions. Form 8-K current reports document material events such as quarterly financial press releases, updated corporate presentations, program data updates from the upliFT-D trial, manufacturing and regulatory milestones, board and committee changes, and the implementation of the 1-for-20 reverse stock split and related Nasdaq listing matters.
Where applicable, investors may also consult proxy materials and other governance-related filings for information on board composition and stockholder approvals, including approvals related to capital structure changes. For a company like Passage Bio, which is advancing a gene therapy candidate through early-stage clinical development, these filings help clarify trial status, manufacturing strategy, and the company’s view of its cash runway and operating priorities.
On Stock Titan, Passage Bio filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand major changes in financial condition, clinical and regulatory plans, and capital structure. Real-time updates from EDGAR ensure that new PASG filings, including 10-K, 10-Q, and 8-K reports, appear promptly, while structured access to filings supports deeper review of the company’s regulatory and disclosure history.
Passage BIO, Inc. reported an insider equity transaction by President and CEO William Chou. On January 8, 2026, 10,000 restricted stock units converted into an equal number of common shares at an exercise price of $0. In connection with this vesting, 4,076 common shares were sold at a weighted average price of $18.4394 per share as part of an issuer-mandated "sell to cover" transaction to satisfy tax withholding obligations, rather than a discretionary sale.
After these transactions, Chou directly held 6,524 common shares and 10,000 RSUs. The RSUs vest in two equal installments, with 50% scheduled to vest on January 8, 2026 and the remaining 50% on January 8, 2027, subject to continued service with Passage BIO.
Passage BIO, Inc. CFO Kathleen Borthwick reported the vesting of equity awards and an associated tax sale. On January 8, 2026, 5,000 restricted stock units converted into common stock at an exercise price of $0, reflecting previously granted compensation.
On the same date, she sold 2,062 shares of common stock at a weighted average price of $18.4394 per share, in an issuer-mandated “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting. The price for these shares came from multiple trades between $18.13 and $19.3061 per share. After these transactions, she directly held 5,402 shares of common stock and 5,000 RSUs.
Passage Bio, Inc. reported in an updated corporate presentation that its preliminary, unaudited cash, cash equivalents and marketable securities position as of December 31, 2025 was approximately $46 million. The company currently expects this cash balance to be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027. These figures were prepared by management, may change as year-end financial statements are finalized, and remain subject to normal review and audit procedures. The updated corporate presentation containing this information has been furnished as an exhibit and is not deemed filed for liability purposes.
A shareholder of PASG has filed a Form 144 notice to potentially sell 4,076 shares of common stock through broker Maxim Group on NASDAQ. The shares to be sold have an aggregate market value of 75,120.00, compared with 3,178,710 shares of the same class reported as outstanding, and the filer lists an approximate sale date of 01/09/2026.
The securities were originally acquired as restricted stock from the issuer on 01/15/2025, with 10,000 shares obtained as compensation and a stated payment date of 01/09/2026. By signing the notice, the selling holder represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
Passage Bio (PASG) filed its Q3 2025 10‑Q, reporting lower operating costs and a narrower loss. Net loss was $7.7 million for the quarter and $32.5 million year‑to‑date, reflecting reduced research and development and general and administrative spending after a January workforce reduction. Other income was supported by interest on cash and sublease income.
Cash and cash equivalents were $52.8 million, up from $37.6 million at year‑end as marketable securities matured and were reinvested in money market funds. Total assets were $74.2 million and total liabilities were $43.0 million, leaving stockholders’ equity at $31.1 million. The company recorded $13.8 million of non‑refundable sublicense and transition services payments related to its Gemma agreements as a current liability, with revenue recognition deferred. Management states cash is sufficient for at least the next 12 months. As of November 6, 2025, 3,178,710 common shares were outstanding. The at‑the‑market facility had $15.8 million of remaining capacity at September 30, 2025.
Passage Bio, Inc. filed a current report to note it issued a press release announcing financial results for the quarter ended September 30, 2025 and updated its corporate presentation.
The press release is furnished under Item 2.02 as Exhibit 99.1, and the presentation is furnished under Item 7.01 as Exhibit 99.2. Both items are furnished, not filed, and are not incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Kathleen Borthwick.
Passage Bio, Inc. reported that on September 16, 2025, board member Saqib Islam resigned from its Board of Directors and from the Board’s Audit Committee, effective immediately. The company stated that his decision was not due to any disagreement with Passage Bio on matters related to operations, policies, or practices.
To address the vacancy, the Board appointed Athena Countouriotis, M.D., to serve on the Audit Committee and reduced the overall Board size from eight to seven members as of the resignation date.
Passage BIO, Inc. (PASG) Form 4: Lynx1 Capital Management LP and Weston Nichols reported insider purchases of Passage BIO common stock on three dates in September 2025. The filings show acquisitions of 325 shares on 09/11/2025 at a weighted average price of $6.9558 (range $6.915–$6.985), 19,783 shares on 09/12/2025 at $6.9908 (range $6.93–$7.00), and 11,900 shares on 09/15/2025 at $6.9895 (range $6.94–$7.00). Following these transactions, the filing reports beneficial ownership of 623,704 shares held indirectly through Lynx1 Master Fund LP, for which Lynx1 Capital Management LP is the investment manager and Weston Nichols is the sole member of the manager's GP. The reporting persons are identified as a director and a 10% owner.
Passage Bio reported a tighter but funded balance sheet with $57.6 million in cash and cash equivalents and total assets of $79.2 million, down from $102.4 million. The company recorded a net loss of $9.4 million for the quarter and $24.8 million for the six months, driven by research and development and general and administrative costs, partially offset by $0.9 million of other income in the quarter.
The company implemented a workforce reduction of about 55% and ceased laboratory operations in Hopewell, resulting in a $2.6 million impairment of long-lived assets and a subsequent sale of substantially all lab equipment for $1.2 million. Passage Bio received $9.7 million of non-refundable sublicense and transition services payments related to amended Gemma sublicenses (additional contractual payments and milestones disclosed) and has $15.8 million capacity remaining under its ATM facility. Management states cash is sufficient to fund operations for at least the next 12 months.
Passage Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and updated its corporate presentation. The press release is attached as Exhibit 99.1 and the presentation as Exhibit 99.2.
The 8-K states these items are furnished, not filed, so they are not subject to Section 18 liability and will not be incorporated by reference into other filings except by specific reference. The text of the filing does not include any numeric financial figures or operational details; the detailed results and presentation slides are contained in the attached exhibits.
FAQ
What is the current stock price of Passage Bio (PASG)?
What is the market cap of Passage Bio (PASG)?
